Financial
Personal
Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody
The combination treatment resulted in increased numbers of anti-cancer tumor-infiltrating T-cells; decreased numbers of anti-cancer response inhibiting tumor-infiltrating myeloid derived suppressor cells; and substantial 84% inhibition of tumor growt
The combination treatment resulted in increased numbers of anti-cancer tumor-infiltrating T-cells; decreased numbers of anti-cancer response inhibiting tumor-infiltrating myeloid derived suppressor cells; and substantial 84% inhibition of tumor growth Read More
